Media News The Challenge of Early-stage Cancer Detection Authors: J Tcherkassova, S Tsurkan, E Klinski and Ricardo Moro UCM Technologies Inc., Toronto, ON, Canada, UCT Research & Development Inc., Toronto, ON, Canada, Pacific Biosciences Research Center, Vancouver, BC, Canada, UCM Technologies Inc., Toronto, ON, CanadaJuly 31, 2024ASCO 2024: ‘CA-62: A new biomarker for the detection of early-stage renal carcinoma’ posterpresentation.July 23, 2024A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1)and early-stage NSC lung cancer detection.June 3, 2023UCT Enters into the National Phase of Patent Application in EU and IndiaDecember 1, 2022UCT Presents New Data at the International Conference in PARIS, FRANCENovember 17, 2022UCT Presents New Data at the 46th International Society of Oncology and Biomarkers (ISOBM) Congress, Bled, SloveniaOctober 12, 2022UCT Publishes a New Positive Result in Cancer Biomarkers JournalOctober 7, 2022UCT Launches US Trail of the CA-62 Early-Stage Cancer MarkerJuly 11, 2022UCT Announces the EURASIAN Patent Granted and the US Patent PendingFebruary 16, 2022UCT Initiates the Authorization Process with the EMA, EUSeptember 6, 2021UCT Develops a Training ProgramAugust 21, 2021UCT Files Patent with United States Patent and Trademark Office for Cancer Test KitsDecember 7, 2020UCT Announces Approval of Cancer Testing KitsApril 2, 2020UCT Presents CA-62 Biomarker Cancer Test at World Cancer Leader SummitOctober 17, 2019How to Detect Cancer: $400,000 for the Most Accurate Cancer TestOctober 18, 2018 Presentations UCT Brief Overview 2022December 20, 2022
